Steve Sabus was named general manager of Astellas Pharma Canada (APCA), effective April 1, 2018. In his new role, he will lead business operations in the country.
Uwe Röhrhoff was named CEO of Perrigo Company following the retirement of John T. Hendrickson.
Timothy Whitten has become president of Taiho Oncology Inc. (U.S.), a subsidiary of Taiho Pharmaceutical Co. Ltd. (Japan).
Christopher O’Brien, M.D., chief medical officer of Neurocrine Biosciences Inc., retired in February 2018 after a transition period with his successor.
Shaun Urban was named president of the Inception Companies.
Wayne Swanton was promoted to executive VP, Global Operations, at Allergan Plc following notification that Rob Stewart, executive VP and chief operating officer, intended to leave Allergan to become president and CEO of Amneal Pharmaceuticals.
Anu Balendran, Ph.D., was appointed VP Business Development at Alligator Bioscience.
Michael Mulhern joined AMRI as CEO, succeeding William S. Marth.
CVS Health introduced Transform Rheumatoid Arthritis Care to help the company’s pharmacy benefit management clients better manage care and costs for rheumatoid arthritis. The program is the latest addition to the company’s suite of condition-specific, highly personalized Transform Care programs and adds value-based management strategies including outcomes-based contracts and a new indication-based formulary for autoimmune conditions to CVS Health’s integrated pharmacy care model
As part of its CareCentered Contracting program, pharmacy benefit manager Prime Therapeutics LLC entered into an outcomes-based contract with Boehringer Ingelheim for Jardiance, an oral type 2 diabetes medicine indicated to reduce the risk of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease.
